The Roots Analysis team is putting in its best effort to offer our clients / readers a reliable source of information, regarding how the pharmaceutical and biotech sectors are coping in the midst of the COVID-19 pandemic. Our intention is to generate realistic insights, based on a variety of factors, which are anticipated to influence both prevalent and future market dynamics. Reach out to us for any help.

Pharmaceutical Anti-Counterfeiting Technologies Market, 2015-2025

  • Lowest Price Guaranteed From USD 2,199

  • Published
    July 2015

  • Pages
    202

  • View Count
    4980

Example Insights

  1. During our research, we identified over 100 technologies (including both authentication and track & trace technologies) developed by over 70 different companies. The landscape seems to be fairly well distributed between authentication and track & trace technologies. Due to the versatility of these technologies, they have wider applications in other industries making it highly lucrative for the current stakeholders.
  2. Some solutions offer multiple features covering all forms of anti-counterfeiting approach; examples include N’Crypt (Amcor), CATS (Authentix), digital DNA (Applied DNA Sciences), nonclonable ID (Bilcaretech), TruTag Platform (TruTag Technologies) and Microparticle Technology (Stealth Mark).
  3. As an industry, the focus seems to be divided between authentication and serialisation technologies; stakeholders view this both as a challenge as well as an opportunity to foster further innovation.There is a wider consensus that puts the onus back on different stakeholders to work collaboratively so that the opportunities can be monetised at a rapid pace; this will result in more robust and complex solutions likely to provide the required security to consumers and companies alike.
  4. Many regions, including the EU and the US, have passed legislations that make serialisation mandatory for every pharmaceutical product. It is a very promising move that is likely to result in a paradigm shift in the way supply chains are managed today. However, there are several implementation hurdles which are expected to result in delays, providing a window of opportunity to the counterfeiters to take advantage of.
  5. It is a known fact that most of counterfeiting happens in India and China. Though the focus on emerging markets has been relatively week so far, manufacturing companies are expected to increase their attention to deploy anti-counterfeiting technologies for products being manufactured or intended to be launched in these regions; going forward, we expect these markets to play a more prominent role in the overall growth of the opportunity.

Overview

The problem of counterfeit products has been a common challenge to all the industries across the globe. However, when it comes to the pharmaceutical industry, the issue primarily revolves around the health of patients rather than revenue losses in the industry. Counterfeit drugs create substantial public health hazards and cause crucial safety concerns. Falsified or substandard drugs can lead to adverse reactions / side effects and consequently lead to the death of a patient.

The major challenge associated with a counterfeit drug is that a non-expert, such as a patient, cannot differentiate between genuine and counterfeit drug without the help of a special instrument or device. The packaging, shape and size of counterfeit drugs are made identical to that of an authentic drug by the counterfeiters. However, counterfeit drugs contain very less or no active ingredient; instead, they contain other useless and harmful materials such as dust, chalk or very low quality active ingredients posing serious threats to the patients. These issues have led to the development of many technologies that can be used to detect whether a drug is legitimate or fake. Apart from these technologies, many other significant measures have been taken by the pharmaceutical companies and government authorities to tackle this growing problem.

The market can be categorised into two segments, Authentication Technologies (the technologies providing overt and covert security features) and Track & Trace Technologies (the technologies facilitating visibility of products throughout the supply chain). Specifically in the Authentication segment, technologies providing covert security features are very popular and occupy a major share in of the overall authentication market. These technologies are very difficult to mimic and require special instruments / devices for verification of drugs by the manufacturers.

Managing supply chain, especially in case of pharmaceutical industry, is a big challenge. Pharmaceuticals supply chains are highly complex and therefore make it an ideal target for counterfeiters. However, recently many developments have taken place to overcome this challenge. Several countries across the globe have passed legislations, making it mandatory to implement serialisation by the manufacturers. Serialisation is being thought as a one stop solution to prevent counterfeiting in the pharmaceutical industry by securing the supply chain.

The field has attracted several companies which have developed many technologies with an aim to prevent counterfeiting in the pharma industry. The overall interest continues to rise as is evident from the number of counterfeit incidents and various laws and legislations being passed throughout the world. Small companies that have developed anti-counterfeiting technologies are likely to play a very active role in the near future.

 

Scope of the Report

The ‘Pharmaceutical Anti-Counterfeiting Technologies, 2015-2025’ report provides a comprehensive study of the growing market of anti-counterfeiting technologies being used in the pharmaceutical industry. This study provides extensive details on technologies which offer overt and covert features to enable verification of drugs. In addition, it reviews the different track and trace technologies which enable tracking of a product through the supply chain. Counterfeiting of products is a big concern in several industries such as electronics, cosmetics, tobacco, wine & spirits and fast moving consumer goods. Specifically, within the pharmaceutical market, the magnitude of the problem is relatively high as it has a direct impact on the health of the wider community. It is worth highlighting that the pharmaceutical market is highly attractive for counterfeiters due to several benefits such as high price of patented drugs, lack of proper legislations and high demand of medicinescompared to their supply. The primary goal of anti-counterfeiting technologies is to prevent counterfeiting of products; this is done by making it difficult to copy patent protected drugs as well as preventing entry of substandard or fake drugs into the product supply chain.

The report covers multiple aspects such as key features of various technologies, scenario based future outlook of the market, SWOT analysis and our opinion on the likely drivers which will influence the market’s evolution. We have provided a holistic view of the market landscape including detailed profiles of leading technologies highlighting the process by which they prevent counterfeiting. Further advancements in such technologies will make them more cost effective, encourage a wider adoption and result in a more mature market in the years to come.

In addition to the key benefits and the likely market drivers, this study also highlights some of the challenges associated with the use and implementation of these technologies in the pharmaceutical industry. Certain technologies require modifications in existing production processes and present operational challenges to the manufacturers. Cost is another factor that can significantly restrain the market.

The report also includes two case studies on serialisation. We have looked at the regulations that have been implemented already or are likely to be implemented to prevent counterfeiting. Most of these regulations favour item level serialisation as a task to be accomplished by the pharmaceutical manufacturers in the near future. However, some stakeholders are of the opinion that authentication technologies are much more effective as anti-counterfeiting measures rather than just providing a unique number to each product (the case of serialisation). The report covers various techniques and measures that have the potential to combat the challenges related to counterfeit medicines.

The scenario based forecast approach identifies short-midterm and long term market evolution for the period 2015-2020 and 2020-2025, respectively. The research, analysis and insights presented in this report are backed by a deep understanding of key insights gathered from both secondary and primary research.

Contents

Chapter 2  provides an executive summary of major highlights captured in the report. It offers a high level view on the likely future of anti-counterfeiting technologies in the pharmaceutical industry.

Chapter 3  provides a general introduction to the anti-counterfeiting technologies. It identifies the needs and challenges faced by the pharmaceutical industry due to counterfeiting and highlights the extent of this problem. We have included examples of the products from leading pharmaceutical companies that have been counterfeited.

Chapter 4  provides a comprehensive analysis of the current market of anti-counterfeiting technologies. It lists more than 100 technologies that can be used to prevent counterfeiting; these technologies have been categorised as authentication technologies (offering overt and / or covert features) and track and trace technologies (including serialisation, RFID, barcodes, e-pedigree / m-pedigree).

Chapter 5  provides details of the well-known and emerging anti-counterfeiting technologies worldwide. This chapter covers insights on the companies developing these technologies as well as details of how the technologies help prevent counterfeiting by highlighting their unique features and applicability.

Chapter 6  presents a detailed discussion covering the developments related to serialisation. As a lot of countries have passed regulations making serialisation mandatory in the near future, there is a dramatic shift currently taking place in terms of how the pharmaceutical supply chains are likely to be managed in the future.

Chapter 7  highlights the likely future evolution of anti-counterfeiting technologies in pharmaceutical industry over the next ten years. We have adopted a scenario based approach to discuss the evolution of authentication technologies offering overt and covert features, across different regions, till 2025.

Chapter 8  provides the SWOT analysis of anti-counterfeiting technologies market giving strategic insights to the major factors that have contributed to the growth of this market. It also highlights the weaknesses and threats that can negatively impact the growth of the market.

Chapter 9  is a collection of interview transcripts; for the purposes of this study, we held discussions with experts from AlpVision, InfraTrac, Sproxil and Jura JSP to ascertain the key strategic initiatives and future roadmap of the industry.

Chapter 10  summarises the overall report. In this chapter, we have provided a recap of the key takeaways and our independent opinion based on the research and analysis described in previous chapters.

Chapter 11  is an appendix, which provides tabulated data and numbers for all the figures presented in the report.

Chapter 12  is an appendix, which provides a list of companies and organisations mentioned in this report.

Table of Contents

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines
 
2. EXECUTIVE SUMMARY
 
3. INTRODUCTION
3.1. Counterfeit Drugs: A Mammoth Challenge to Overcome in Pharmaceutical Industry
3.2. Different Definitions of a Counterfeit Drug
3.3. Factors Encouraging Counterfeiting in Pharmaceutical Industry
3.4. Need for Anti-Counterfeiting Measures/Technologies
3.4.1. Counterfeit Drug Cases: Yearly Distribution
 
3.5. Identification and Assessment of Risks From Counterfeiting
3.5.1. Determining The Severity of a Counterfeit Incident
3.5.2. Determining The Possibility of Occurrence of a Counterfeit Incident
 
3.6. Recent Counterfeiting Incidents in Pharmaceutical Industry
3.6.1. Counterfeit Cialis (Tadalafil) Tablets
3.6.2. Counterfeit Viagra (Sildenafil Citrate) Tablets
3.6.3. Counterfeit Serostim (Somatropin) Drug
3.6.4. Counterfeit Procrit (Epoetin Alfa) Injection
3.6.5. Other Counterfeited Drugs
 
3.7. Extent of Counterfeiting Through Online Pharmacies
3.7.1. Russia Becoming a Major Source of Online Counterfeit Drugs Market
3.7.2. Presence of Counterfeit Botox in an Online Pharmacy
3.7.3. Hundreds of Counterfeiters Arrested in China for Selling Counterfeit Drugs Over the Internet
3.7.4. Novo Nordisk’s Stolen Human Growth Hormone Sold Online
3.7.5. Coordinated Sweep to Attack Online Pharmacies Selling Unauthorised Drugs
3.7.6. A Hint to Source of Drugs for Illegal Online Pharmacies
3.7.7. Launch of BeSafeRx by FDA to Create Awareness About Online Pharmacies
3.8. Initiatives Taken by Pharmaceutical Companies / Government Authorities To Combat Counterfeiting Problem
3.8.1. International Medical Product Anti-Counterfeiting Task Force (IMPACT)
3.8.2. Operation Pangea
3.8.3. Establishment of Interface Public-Members (IPM) by World Customs Organisation
3.8.4. Launch of PASS System by Pfizer
3.8.5. Sanofi’s Commitment: Creation of Central Anti-Counterfeiting Laboratory
3.8.6. Role of Eli Lilly And Company in Fighting Counterfeiters
3.8.7. Merck’s Responsibility Towards Prevention of Counterfeiting in Pharma Industry
 
3.9. Different Anti-Counterfeiting Technologies
3.9.1. Authentication Technologies Providing Overt Features
3.9.2. Authentication Technologies Providing Covert Features
3.9.3. Track and Trace Technologies
 
4. MARKET OVERVIEW
4.1. Chapter Overview
4.2. Anti-Counterfeiting Technologies
4.3. Platforms are Well-Distributed Across Different Technologies
4.4. Technologies Providing Overt Features
4.4.1. Holograms
4.4.2. Colour Shift Inks / Markings
4.4.3. On-Product Markings
4.4.4. Security Graphics
4.4.5. Other Technologies
 
4.5. Technologies Providing Covert Features
4.5.1. Embedded Graphics / Labels
4.5.2. Invisible Inks / Printings
4.5.3. Digital Watermarks and Hidden Marks
4.5.4. DNA Markers / Taggants
4.5.5. Other Technologies
4.6. Track and Trace Technologies
4.6.1. Serialisation
4.6.2. Barcode
4.6.3. RFID
4.6.4. Unique Surface Marking
4.6.5. e-pedigree/m-pedigree
4.6.6. Other Track and Trace Technologies
 
4.7. Comparison Amongst Anti-Counterfeiting Technologies
4.7.1. Manufacturer’s Perspective
4.7.1.1. Level of Security
4.7.1.2. Implementation Ease
4.7.1.3. Robustness/Durability
4.7.2. User’s Perspective
4.7.2.1. Cost
4.7.2.2. User Friendliness
4.7.2.3. Level of Complexity
 
5. AUTHENTICATION: KEY PLAYERS AND TECHNOLOGIES
5.1. Chapter Overview
5.2. Technologies by AlpVision
5.2.1. About AlpVision
5.2.2. Anti Counterfeiting Solutions
5.2.2.1. Cryptoglyph
5.2.3. Fingerprint
5.2.4. Benefits for Manufacturers and Consumers
5.2.5. Krypsos
 
5.3. Technologies by Applied DNA Sciences
5.3.1. About Applied DNA Sciences
5.3.2. SigNature® DNA Technology
5.3.2.1. SigNature® DNA Marker Production
5.3.2.2. Applications of SigNature® DNA Technology
5.3.3. digitalDNA® Technology
5.3.3.1. digitalDNA® Deployment
5.3.3.2. Applications of digitalDNA® Technology
5.3.4. Recent Developments
5.3.4.1. Launch of DNA Taggant and On-Site Authentication for Pharmaceutics
5.3.4.2. Launch of DNA BeaconTM
5.3.4.3. Collaboration with ITW Pillar Technologies
 
5.4. Technology by InfraTrac
5.4.1. About InfraTrac
5.4.2. Anti Counterfeiting Solutions
5.4.2.1. Usage
5.4.2.2. Advantages / Features of InfraTrac
5.4.2.3. Benefits for Manufacturers
 
5.5. Technologies by Amcor
5.5.1. About Amcor
5.5.2. N’Crypt® Security Solution
5.5.3. Benefits of N’Crypt® Security Solution
 
5.6. Technologies by LinkSmart
5.6.1. About LinkSmart technologies
5.6.2. About smartDNATM Technology
5.6.2.1. Working of smartDNATM Technology
5.6.2.2. Benefits for Manufacturers
 
5.7. Technologies by VorVision®
5.7.1. About VorVision®
5.7.2. VorCode Technology
5.7.3. Working of the Technology
 
5.8. Technologies by Schreiner ProSecure
5.8.1. Holograms
5.8.2. Colour Shifting Inks
5.8.3. LaserSecure
5.8.4. FluxSecure
5.8.5. DNASecure
5.8.6. BitSecure
5.8.7. Track and Trace Technologies
 
5.9. Technologies by ACG-Worldwide
5.9.1. Brandshield Printing
5.9.2. Brandshield 3600 Printing
5.9.3. Engraving on Capsule
5.9.4. Tablets of Complex Shape
5.9.5. Brandshield Galaxy
5.9.6. Verif-i
 
5.10. Other Technologies
5.10.1. DigiTrack by Catalent Pharma
5.10.2. DNA Matrix by DNA Technologies
5.10.3. Technologies by Everest Holovisions
5.10.3.1. Holographic Shrink Sleeves
5.10.3.2. Holographic Film
5.10.4. Technologies by Dupont
5.10.4.1. Izon Technology
5.10.4.2. Dupont Traceology
5.10.5. Microparticle Technology by StealthMark
5.10.6. Technologies by Raumedic
5.10.6.1. Micro-Particle Technology
5.10.6.2. UV-Marking
5.10.7. µicroTag Technology by MicroTag Temed
5.10.8. SAVEmed by Nano 4 U
5.10.9. TagSure Technology by InkSure
5.10.10. TruScan by ThermoScientific
 
6. TRACK AND TRACE: KEY TECHNOLOGIES AND THE CONCEPT OF SERIALISATION
6.1. Chapter Overview
6.2. Serialisation: What Does it Mean?
6.3. Benefits of Serialisation For Pharmaceutical Manufacturers
6.4. Legislations / Laws / Acts in Favour of Serialisation
6.4.1. The Drug Quality and Security Act (DQSA-H.R. 3204)
6.4.2. The EU Directive on Falsified Medicines
6.4.3. Legislations / Regulations in Asian Countries
6.4.4. Legislations / Regulations In Other Countries
6.5. Challenges to Implementation of Serialisation
 
6.6. Track and Trace Technologies
6.6.1. Technology by Axway
6.6.1.1. About Axway
6.6.1.2. Axway Track and Trace Technology
 
6.6.2. Technologies by Sproxil
6.6.2.1. Mobile Product Authentication (MPA)
6.6.2.2. Cascading Authentication
 
6.6.3. Technology by mPedigree Network
6.6.3.1. About mPedigree Network
6.6.3.2. GoldkeysTM Platform
 
6.6.4. Technologies by SecureRF
6.6.4.1. Veridify
6.6.4.2. LIME Tag Solution
 
6.6.5. Technology by TruTag® Technologies
6.6.5.1. About TruTag® Technologies
6.6.5.2. TruTag® MicroTag Platform
 
6.6.6. Other Track and Trace Technologies
6.6.6.1. AuthentiTrack by Covectra
6.6.6.2. Comprehensive Authentication and Traceability System (CATS) by Authentix
6.6.6.3. CPS (Carton Printing and Verification System) by Bosch Packaging Systems
6.6.6.4. DVAC (Drug Verification and Compliance) Framework by Portalis
6.6.6.5. Life Sciences Cloud by TraceLink
6.6.6.6. Medtracker by Atlantic Zeiser
6.6.6.7. Naginels Technology
6.6.6.8. nonClonableID Technology by Bilcare Technologies
6.6.6.9. Technologies by PharmaSecure
6.6.6.10. StratOmark by Sekuworks
 
6.7. RFID Based Technologies
6.7.1. RFID Platform by Alien Technology
6.7.2. RFID by 3M
6.7.3. RFID Platform by SMARTRAC
6.7.4. Intelligent RFID by EM Microelectronics
6.7.5. RFID Platform by Avery Dennison
 
6.8. Case Studies On Serialisation
6.8.1. Case Study 1: Cognizant-An IT Services Company Providing Serialisation Solution
6.8.2. Case Study 2: Recipharm-A Contract Development and Manufacturing Organisation
6.9. Serialisation: Mapping the Current Scenario
 
7. MARKET FORECAST
7.1. Chapter Overview
7.2. Forecast Methodology
7.3. Key Assumptions
7.4. Overall Pharma Anti-Counterfeiting Technologies Market, 2015-2025
7.5. Anti-Counterfeiting Technologies Providing Covert Features, 2015-2025
7.6. Anti-Counterfeiting Technologies Providing Overt Features, 2015-2025
7.7. Regional Market Forecast
7.8. Comparative Summary
 
8. SWOT ANALYSIS
8.1. Chapter Overview
8.2. Strengths
8.2.1. Technologies Offer Multiple Security Features
8.2.2. User Friendliness
8.2.3. Unchanged Production Lines
 
8.3. Weaknesses
8.3.1. Some Technologies Are Easy to Replicate
8.3.2. Technologies are Costly to Deploy
8.3.3. Lack of End User Awareness
 
8.4. Opportunities
8.4.1. Serialisationas a Mandatory Process
8.4.2. Growing Presence in Emerging Markets
8.4.3. Versatility of Technologies
 
8.5. Threats
8.5.1. Divided Focus Between Authentication and Serialisation
8.5.2. Challenging Timelines
 
9. INTERVIEW TRANSCRIPTS
9.1. Interview 1: Dr. Fred Jordan, CEO, AlpVision
9.2. Interview 2: Jaime Stern, Director of Sales, Sproxil
9.3. Interview 3: Dr. Sharon Flank, CEO, InfraTrac
9.4. Interview 4: Roger Pallacivini, Sales Director Europe, Jura JSP GmbH
 
10. CONCLUSION
10.1. With a Huge Market Potential, Anti-Counterfeiting Technologies Market to Grow Steadily
10.2. Serialisation to Dominate the Discussions in the Short Term
10.3. Solutions Offering Covert Features will Gain Additional Market Share Within Authentication Technologies
10.4. The US and The EU will Remain Leading Contributors to Anti-Counterfeiting Technologies
10.5. Concluding Remarks
 
11. APPENDIX 1: TABULATED DATA
 
12. APPENDIX 2: COMPANIES AND ORGANISATIONS LISTED

List of Figures

Figure 3.1  Counterfeit Drug Cases Opened: Distribution by Year
Figure 3.2 Number of Counterfeit Drugs Cases Detected: Distribution by Year
Figure 3.3 Geographical Distributions of the Counterfeit Drug Cases in 2014
Figure 4.1  Anti-Counterfeiting Technologies: Distribution by Type of Features
Figure 4.2 Comparisons Amongst Anti-Counterfeiting Technologies
Figure 6.1  Serialisation: Mapping the Current Scenario
Figure 7.1 Future Market Scenarios: Description
Figure 7.2  Overall Pharma Anti-Counterfeiting Technologies Market, Short-Midterm (2015-2020): Base Scenario (USD Million)
Figure 7.3  Overall Pharma Anti-Counterfeiting Technologies Market, Long term (2020-2025): Base Scenario (USD Million)
Figure 7.4  Anti-Counterfeiting Technologies Providing Covert Features, Short-Midterm (2015-2020): Base Scenario (USD Million)
Figure 7.5  Anti-Counterfeiting Technologies Providing Covert Features, Long Term (2020-2025): Base Scenario (USD Million)
Figure 7.6  Anti-Counterfeiting Technologies Providing Overt Features, Short-Midterm (2015-2020): Base Scenario (USD Million)
Figure 7.7  Anti-Counterfeiting Technologies Providing Overt Features, Long Term (2020-2025): Base Scenario (USD Million
Figure 7.8  Regional Market Forecast, Short-Midterm (2015-2020): Base Scenario (USD Million)
Figure 7.9  Regional Market Forecast, Long Term (2020-2025): Base Scenario (USD Million)
Figure 7.10  Market Scenarios, Comparative Positioning (USD Million)
Figure 7.11  Market Scenarios: Comparative Annual Growth Rates
Figure 10.1  Anti-Counterfeiting Technologies: Comparative Market Evolution Scenarios, 2015, 2020, 2025 (USD Million)
Figure 10.2  Anti-Counterfeiting Technologies: Regional Comparative Market Evolution, Base Case Scenario, 2015, 2020, 2025 (USD Million)

List of Tables

Table 4.1  List of Anti-Counterfeiting Technologies
Table 4.2  Anti-Counterfeiting Technologies: Distribution by Features
Table 4.3  Technologies Providing Overt Features: Advantages and Disadvantages
Table 4.4  List of Hologram Technologies
Table 4.5  List of Colour Shift Ink / Marking Technologies
Table 4.6  List of On-Product Marking Technologies
Table 4.7  List of Security Graphic Technologies
Table 4.8  List of Other Technologies Providing Overt Features
Table 4.9  Technologies Providing Covert Features: Advantages and Disadvantages
Table 4.10  List of Embedded Graphic / Label Technologies
Table 4.11  List of Invisible Ink / Printing Technologies
Table 4.12  List of Digital Watermark and Hidden Marking Technologies
Table 4.13  List of DNA Marker / Taggant Technologies
Table 4.14  List of Other Technologies Providing Covert Features
Table 4.15  Track and Trace Technologies: Advantages and Disadvantages
Table 4.16  List of Serialisation Technologies
Table 4.17  List of Barcode Technologies
Table 4.18  List of RFID Technologies
Table 4.19  List of Unique Surface Marking Technologies
Table 4.20  List of e-pedigree/m-pedigree Technologies
Table 4.21  List of Other Track and Trace Technologies
Table 8.1  SWOT Analysis
Table 11.1  Counterfeiting Drug Cases Opened: Distribution by Year
Table 11.2  Number of Counterfeit Drugs Cases Detected: Distribution by Year
Table 11.3  Geographical Distribution of Counterfeit Drug Cases in 2014
Table 11.4  Overall Pharma Anti-Counterfeiting Technologies Market, Short -Midterm (2015-2020): Conservative Scenario (USD Million)
Table 11.5  Overall Pharma Anti-Counterfeiting Technologies Market, Short -Midterm (2015-2020): Base Scenario (USD Million)
Table 11.6  Overall Pharma Anti-Counterfeiting Technologies Market, Short -Midterm (2015-2020): Optimistic Scenario (USD Million)
Table 11.7  Overall Pharma Anti-Counterfeiting Technologies Market, Long term (2020-2025): Conservative Scenario (USD Million)
Table 11.8  Overall Pharma Anti-Counterfeiting Technologies Market, Long term (2020-2025): Base Scenario (USD Million)
Table 11.9  Overall Pharma Anti-Counterfeiting Technologies Market, Long term (2020-2025): Optimistic Scenario (USD Million)
Table 11.10  Anti-Counterfeiting Technologies Providing Overt Features, Short -Midterm (2015-2020): Conservative Scenario (USD Million)
Table 11.11  Anti-Counterfeiting Technologies Providing Overt Features, Short -Midterm (2015-2020): Base Scenario (USD Million)
Table 11.12  Anti-Counterfeiting Technologies Providing Overt Features, Short -Midterm (2015-2020): Optimistic Scenario (USD Million)
Table 11.13  Anti-Counterfeiting Technologies Providing Overt Features, Long term (2020-2025): Conservative Scenario (USD Million)
Table 11.14  Anti-Counterfeiting Technologies Providing Overt Features, Long term (2020-2025): Base Scenario (USD Million)
Table 11.15  Anti-Counterfeiting Technologies Providing Overt Features, Long term (2020-2025): Optimistic Scenario (USD Million)
Table 11.16  Anti-Counterfeiting Technologies Providing Covert Features, Short -Midterm (2015-2020): Conservative Scenario (USD Million)
Table 11.17  Anti-Counterfeiting Technologies Providing Covert Features, Short -Midterm (2015-2020): Base Scenario (USD Million)
Table 11.18  Anti-Counterfeiting Technologies Providing Covert Features, Short -Midterm (2015-2020): Optimistic Scenario (USD Million)
Table 11.19  Anti-Counterfeiting Technologies Providing Covert Features, Long term (2020-2025): Conservative Scenario (USD Million)
Table 11.20  Anti-Counterfeiting Technologies Providing Covert Features, Long term (2020-2025): Base Scenario (USD Million)
Table 11.21  Anti-Counterfeiting Technologies Providing Covert Features, Long term (2020-2025): Optimistic Scenario (USD Million)
Table 11.22  Holograms Market Forecast, Short -Midterm (2015-2020): Conservative Scenario (USD Million)
Table 11.23  Holograms Market Forecast, Short -Midterm (2015-2020): Base Scenario (USD Million)
Table 11.24  Holograms Market Forecast, Short -Midterm (2015-2020): Optimistic Scenario (USD Million)
Table 11.25  Holograms Market Forecast, Long term (2020-2025): Conservative Scenario (USD Million)
Table 11.26  Holograms Market Forecast, Long term (2020-2025): Base Scenario (USD Million)
Table 11.27 Holograms Market Forecast, Long term (2020-2025): Optimistic Scenario (USD Million)
Table 11.28  Colour Shift Inks Market Forecast, Short -Midterm (2015-2020): Conservative Scenario (USD Million)
Table 11.29  Colour Shift Inks Market Forecast, Short -Midterm (2015-2020): Base Scenario (USD Million)
Table 11.30  Colour Shift Inks Market Forecast, Short -Midterm (2015-2020): Optimistic Scenario (USD Million)
Table 11.31  Colour Shift Inks Market Forecast, Long term (2020-2025): Conservative Scenario (USD Million)
Table 11.32  Colour Shift Inks Market Forecast, Long term (2020-2025): Base Scenario (USD Million)
Table 11.33  Colour Shift Inks Market Forecast, Long term (2020-2025): Optimistic Scenario (USD Million)
Table 11.34  Security Graphics Market Forecast, Short -Midterm (2015-2020): Conservative Scenario (USD Million)
Table 11.35  Security Graphics Market Forecast, Short -Midterm (2015-2020): Base Scenario (USD Million)
Table 11.36  Security Graphics Market Forecast, Short -Midterm (2015-2020): Optimistic Scenario (USD Million)
Table 11.37  Security Graphics Market Forecast, Long term (2020-2025): Conservative Scenario (USD Million)
Table 11.38  Security Graphics Market Forecast, Long term (2020-2025): Base Scenario (USD Million)
Table 11.39  Security Graphics Market Forecast, Long term (2020-2025): Optimistic Scenario (USD Million)
Table 11.40  Other Technologies Market Forecast, Short -Midterm (2015-2020): Conservative Scenario (USD Million)
Table 11.41  Other Technologies Market Forecast, Short -Midterm (2015-2020): Base Scenario (USD Million)
Table 11.42  Other Technologies Market Forecast, Short -Midterm (2015-2020): Optimistic Scenario (USD Million)
Table 11.43  Other Technologies Market Forecast, Long term (2020-2025): Conservative Scenario (USD Million)
Table 11.44  Other Technologies Market Forecast, Long term (2020-2025): Base Scenario (USD Million)
Table 11.45  Other Technologies Market Forecast, Long term (2020-2025): Optimistic Scenario (USD Million)
Table 11.46  Invisible Printing Technologies Market Forecast, Short -Midterm (2015-2020): Conservative Scenario (USD Million)
Table 11.47  Invisible Printing Technologies Market Forecast, Short -Midterm (2015-2020): Base Scenario (USD Million)
Table 11.48  Invisible Printing Technologies Market Forecast, Short -Midterm (2015-2020): Optimistic Scenario (USD Million)
Table 11.49  Invisible Printing Technologies Market Forecast, Long term (2020-2025): Conservative Scenario (USD Million)
Table 11.50  Invisible Printing Technologies Market Forecast, Long term (2020-2025): Base Scenario (USD Million)
Table 11.51  Invisible Printing Technologies Market Forecast, Long term (2020-2025): Optimistic Scenario (USD Million)
Table 11.52 Digital Watermarks Technologies Market Forecast, Short -Midterm (2015-2020): Conservative Scenario (USD Million)
Table 11.53  Digital Watermarks Technologies Market Forecast, Short -Midterm (2015-2020): Base Scenario (USD Million)
Table 11.54  Digital Watermarks Technologies Market Forecast, Short -Midterm (2015 -2020): Optimistic Scenario (USD Million)
Table 11.55  Digital Watermarks Technologies Market Forecast, Long term (2020-2025): Conservative Scenario (USD Million)
Table 11.56  Digital Watermarks Technologies Market Forecast, Long term (2020-2025): Base Scenario (USD Million)
Table 11.57  Digital Watermarks Technologies Market Forecast, Long term (2020-2025): Optimistic Scenario (USD Million)
Table 11.58  DNA Markers / Taggant Technologies Market Forecast, Short -Midterm (2015-2020): Conservative Scenario (USD Million)
Table 11.59  DNA Markers / Taggant Technologies Market Forecast, Short -Midterm (2015-2020): Base Scenario (USD Million)
Table 11.60  DNA Markers / Taggant Technologies Market Forecast, Short -Midterm (2015-2020): Optimistic Scenario (USD Million)
Table 11.61 DNA Markers / Taggant Technologies Market Forecast, Long term (2020-2025): Conservative Scenario (USD Million)
Table 11.62 DNA Markers / Taggants Technologies Market Forecast, Long term (2020-2025): Base Scenario (USD Million)
Table 11.63  DNA Markers / Taggants Technologies Market Forecast, Long term (2020 -2025): Optimistic Scenario (USD Million)
Table 11.64  Hidden Marks and Printing Technologies Market Forecast, Short -Midterm (2015-2020): Conservative Scenario (USD Million)
Table 11.65  Hidden Marks and Printing Technologies Market Forecast, Short -Midterm (2015-2020): Base Scenario (USD Million)
Table 11.66  Hidden Marks and Printing Technologies Market Forecast, Short -Midterm (2015-2020): Optimistic Scenario (USD Million)
Table 11.67  Hidden Marks and Printing Technologies Market Forecast, Long term (2020-2025): Conservative Scenario (USD Million)
Table 11.68  Hidden Marks and Printing Technologies Market Forecast, Long term (2020-2025): Base Scenario (USD Million)
Table 11.69  Hidden Marks and Printing Technologies Market Forecast, Long term (2020-2025): Optimistic Scenario (USD Million)
Table 11.70  Other Technologies Market Forecast, Short -Midterm (2015-2020): Conservative Scenario (USD Million)
Table 11.71  Other Technologies Market Forecast, Short -Midterm (2015-2020): Base Scenario (USD Million)
Table 11.72  Other Technologies Market Forecast, Short -Midterm (2015-2020): Optimistic Scenario (USD Million)
Table 11.73  Other Technologies Market Forecast, Long term (2020-2025): Conservative Scenario (USD Million)
Table 11.74  Other Technologies Market Forecast, Long term (2020-2025): Base Scenario (USD Million)
Table 11.75  Other Technologies Market Forecast, Long term (2020-2025): Optimistic Scenario (USD Million)
Table 11.76  Regional Market Forecast: North America, Short -Midterm (2015-2020): Conservative Scenario (USD Million)
Table 11.77  Regional Market Forecast: North America, Short -Midterm (2015-2020): Base Scenario (USD Million)
Table 11.78  Regional Market Forecast: North America, Short -Midterm (2015-2020): Optimistic Scenario (USD Million)
Table 11.79  Regional Market Forecast: North America, Long term (2020-2025): Conservative Scenario (USD Million)
Table 11.80  Regional Market Forecast: North America, Long term (2020-2025): Base Scenario (USD Million)
Table 11.81  Regional Market Forecast: North America, Long term (2020-2025): Optimistic Scenario (USD Million)
Table 11.82  Regional Market Forecast: EU 5, Short -Midterm (2015-2020): Conservative Scenario (USD Million)
Table 11.83  Regional Market Forecast: EU 5, Short -Midterm (2015-2020): Base Scenario (USD Million)
Table 11.84  Regional Market Forecast: EU 5, Short -Midterm (2015-2020): Optimistic Scenario (USD Million)
Table 11.85  Regional Market Forecast: EU 5, Long term (2020-2025): Conservative Scenario (USD Million)
Table 11.86  Regional Market Forecast: EU 5, Long term (2020-2025): Base Scenario (USD Million)
Table 11.87 Regional Market Forecast: EU 5, Long term (2020-2025): Optimistic Scenario (USD Million)
Table 11.88  Regional Market Forecast: Developed Asia, Short -Midterm (2015-2020): Conservative Scenario (USD Million)
Table 11.89  Regional Market Forecast: Developed Asia, Short -Midterm (2015-2020): Base Scenario (USD Million)
Table 11.90  Regional Market Forecast: Developed Asia, Short -Midterm (2015-2020): Optimistic Scenario (USD Million)
Table 11.91  Regional Market Forecast: Developed Asia, Long term (2020-2025): Conservative Scenario (USD Million)
Table 11.92  Regional Market Forecast: Developed Asia, Long term (2020-2025): Base Scenario (USD Million)
Table 11.93  Regional Market Forecast: Developed Asia, Long term (2020-2025): Optimistic Scenario (USD Million)
Table 11.94  Regional Market Forecast: Rest of the World, Short -Midterm (2015-2020): Conservative Scenario (USD Million)
Table 11.95  Regional Market Forecast: Rest of the World, Short -Midterm (2015-2020): Base Scenario (USD Million)
Table 11.96  Regional Market Forecast: Rest of the World, Short -Midterm (2015-2020): Optimistic Scenario (USD Million)
Table 11.97  Regional Market Forecast: Rest of the World, Long term (2020-2025): Conservative Scenario (USD Million)
Table 11.98  Regional Market Forecast: Rest of the World, Long term (2020-2025): Base Scenario (USD Million)
Table 11.99  Regional Market Forecast: Rest of the World, Long term (2020-2025): Optimistic Scenario (USD Million)
Table 11.100  Market Scenarios, Comparative Positioning (USD Million)
Table 11.101  Market Scenarios, Comparative Annual Growth Rates (USD Million)
Table 11.102  Anti-Counterfeiting Technologies Market: Comparative Market Evolution Scenarios, 2015, 2020, 2025 (USD Million)

Listed Companies

Following Companies / Organisations / Government Agencies have been mentioned in this report:

  1. 3M
  2. 3S Simons Security Systems
  3. ACG-Worldwide
  4. Acsis
  5. Alcan Packaging
  6. Alien Technology
  7. Alliance for Safe Online Pharmacies
  8. AlpVision
  9. Amcor
  10. Amgen
  11. Applied DNA Sciences
  12. Atlantic Zeiser
  13. Authentix
  14. Avery Dennison
  15. Axway
  16. Ball Packaging
  17. Bilcaretech
  18. Biocode
  19. Bosch Packaging Technology
  20. Canadadrugs.com
  21. Catalent Pharma
  22. Cellular Bioengineering
  23. Central Anti-Counterfeiting Laboratory
  24. Chesapeake (Acquired by The Carlyle Group)
  25. Cognizant
  26. Confidex
  27. Coresonant
  28. Covectra
  29. Deutsche Welle
  30. DiNova Venture Capital
  31. DNA Technologies
  32. Dupont
  33. Eli Lilly and Company
  34. EM Microelectronics
  35. European Alliance of Access to Safe Medicines
  36. European Medicines Agency
  37. Everest Holovisions
  38. Flint Group
  39. Genzyme
  40. Green Project Inc
  41. IC-Tag Solutions
  42. Impinj
  43. InfraTrac
  44. Ingenia Technology
  45. InkSure Technologies
  46. Intermec
  47. International Medical Product Anti-Counterfeiting Task Force (IMPACT)
  48. Interpol
  49. Invengo
  50. Isotag
  51. ITW Pillar Technologies
  52. Jura JSP
  53. Klocke Group
  54. Kutterer&Mauer AG
  55. Lab-ID
  56. Laxcen
  57. LinkSmart Technologies
  58. Maryland School of Pharmacy
  59. Merck
  60. Merck Serono
  61. MetalCraft
  62. Micros Chip
  63. MicroTagTemed Ltd.
  64. Microtrace Solutions
  65. Mobia Solutions
  66. mPedigree
  67. Nano 4 U
  68. National Association of Boards of Pharmacy
  69. Neosid
  70. North America Security Products Organisation Company
  71. NovaVision
  72. Novo Nordisk
  73. Oat Systems
  74. Office of Criminal Investigations
  75. Omni ID
  76. Omnia
  77. Ortho biotech
  78. Ortho-McNeil Pharmaceuticals
  79. Pacific Holovisions
  80. Permanent Forum on International Pharmaceutical Crime (PFIPC)
  81. Pfizer
  82. PharmaSecure
  83. PhotoSecure
  84. Portalis
  85. PTS Intermediate Holdings LLC
  86. Raumedic
  87. Recipharm
  88. Rehau Group
  89. Robert Bosch GmbH
  90. Saffron Hill Ventures
  91. Sanofi Aventis
  92. Schreiner ProSecure
  93. SecureRF
  94. SecureSpin Systems
  95. Sekuworks
  96. Siemens
  97. SKAI Ventures
  98. Smartrac
  99. Sproxil
  100. Stealth Co. Inc
  101. Stealth Mark
  102. Tagsys
  103. Themis Medicare
  104. Thermo Scientific
  105. TopFlight Corporation
  106. Total Brand Security
  107. TraceLink Inc
  108. TruTag Technologies
  109. United States Food and Drug Administration
  110. Universal Postal Union
  111. Universal Corporation Limited
  112. UPM Raflatac
  113. Verify Brands
  114. Videojet
  115. ViiV Healthcare
  116. Vordata
  117. Wave-Logic
  118. WaveTrend
  119. Wellness Center USA Inc
  120. Wendell Smith
  121. World Customs Organisations
  122. World Health Organisation
  123. WuXiPharmaTech
  124. Xerafy
  125. Zebra Technologies

Request Customization

Please select a suitable option for customization in the report

PRICING DETAILS

USD 2,199

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print read more

This license grants the right of use of the purchased report by the employees of a business unit at a particular site / office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple read more

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm / enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the read more

Discounts available for multiple report purchases
sales@rootsanalysis.com